Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Open access
Lian, Shu, Xie, Ruizhi, Ye, Yuying, Lu, Yusheng, Cheng, Yunlong, Xie, Xiaodong, Li, Shuhui, Jia, Lee · 2019 · Scientific Reports

Abstract

Carcinoma metastasis is triggered by a subpopulation of circulating tumor cells (CTCs). And single immune checkpoint therapy is not good enough to inhibit CTC-induced metastasis. Here, we demonstrate that simultaneously blocking CD274 (programmed death ligand 1, PD-L1 or B7-H1) and CD47 checkpoints which were respectively signal of “don’t find me” and “don’t eat me” on CTCs by corresponding antibodies could enhance the inhibition tumor growth than single CD274 or CD47 antibody alone.In vitro flow cytometry data proved that CD47 and CD274 were overexpressed on the tested mouse tumor cell lines. The antibodies could effectively block the expressions of CD47 and CD274 on the cell surface and stably attached to tumor cell surface for several hours. The simultaneous blockade on both CD47 and CD274 checkpoints inhibited tumor growth and CTCs metastasis more potently than a single antibody inhibition or blank control on 4T1 tumor mouse model in vivo. Our results demonstrated that simultaneous dual targeting immune checkpoints, i.e., CD47 and CD274, by using specific antibodies may be more effective as an immunotherapeutics on CTCs than a CD47 or CD274 alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-40241-1

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Flow cytometric analysis of CD47 and CD274 expression of four mouse cancer cells (4T1, LCC, B16F10 and CT26). (B,E) Flow cytometric analysis the CD47 and CD274 proteins expression on 4T1 cells treated by different antibodies treatment. Control, isolated control; C, cells alone; lg G, the 4T1 cells (105) were incubated with 6 μg anti-lg G; 6 CD47/CD274, the 4T1 cells (105) were incubated with 6 μg anti-CD47/CD274. Error bars show mean ± SEM (**P < 0.01).
Figure 1 (A) Flow cytometric analysis of CD47 and CD274 expression of four mouse cancer cells (4T1, LCC, B16F10 and CT26). (B,E) Flow cytometric analysis the CD47 and CD274 proteins expression on 4T1 cells treated by different antibodies treatment. Control, isolated control; C, cells alone; lg G, the 4T1 cells (105) were incubated with 6 μg anti-lg G; 6 CD47/CD274, the 4T1 cells (105) were incubated with 6 μg anti-CD47/CD274. Error bars show mean ± SEM (**P < 0.01).CC BY · PubMed Central
Figure 2 (A–D) Flow cytometric analysis showed percentages of FITC+ CD47 antibody bind to Hoechst 33258+ 4T1 cells for 0 h (A) or 3 h (B) and PE+ CD274 antibody bind to Hoechst 33258+ 4T1 cells in whole blood for 0 h (C) or 3 h (D). (E) Cell viability of 4T1 cells incubated with mouse blood monocyte. (F) Schematic diagram depicts that dual inhibition on both CD47 and PD-L1 changes immune evasion to immune activation by T cells and NK cells.
Figure 2 (A–D) Flow cytometric analysis showed percentages of FITC+ CD47 antibody bind to Hoechst 33258+ 4T1 cells for 0 h (A) or 3 h (B) and PE+ CD274 antibody bind to Hoechst 33258+ 4T1 cells in whole blood for 0 h (C) or 3 h (D). (E) Cell viability of 4T1 cells incubated with mouse blood monocyte. (F) Schematic diagram depicts that dual inhibition on both CD47 and PD-L1 changes immune evasion to immune activation by T cells and NK cells.CC BY · PubMed Central
Figure 3 (A) Tumor nodules in the lungs of the treated mice developed within 24 days after injection of the 4T1 cells. (B) The body weight variation of 4T1 tumor-model mice during the treatments. (C) The gross appearance of tumor nodules of 4T1 (shown in arrows) in lungs after fixation with Bouin’s solution for 24 h. (D) Histological staining of tumor-bearing lung tissue section with H&E after different treatment, amplification × 100. PBS. PBS only, Control. Tumors only, lg G. Tumors with control lg G, CD47. Tumors with anti-CD47, CD274. Tumors with anti-CD274, CD47 + CD274. Tumors with anti-CD47 and anti-CD274.
Figure 3 (A) Tumor nodules in the lungs of the treated mice developed within 24 days after injection of the 4T1 cells. (B) The body weight variation of 4T1 tumor-model mice during the treatments. (C) The gross appearance of tumor nodules of 4T1 (shown in arrows) in lungs after fixation with Bouin’s solution for 24 h. (D) Histological staining of tumor-bearing lung tissue section with H&E after different treatment, amplification × 100. PBS. PBS only, Control. Tumors only, lg G. Tumors with control lg G, CD47. Tumors with anti-CD47, CD274. Tumors with anti-CD274, CD47 + CD274. Tumors with anti-CD47 and anti-CD274.CC BY · PubMed Central
Figure 4 In vivo anti-tumor efficacy of two antibody blockade both CD47 antibody and CD274 antibody in 4T1 tumor cells. (A) Flow cytometry sorting graphs showing how to distinguish unwanted noise from gated. (B) Schema for two antibodies blockade in immunotherapy. (C–E) The percent of T cells, NK cells and NKT cells in leukocyte since the start of the injection (*P < 0.05, **P < 0.01 and ***P < 0.001). (F–H) The percentage activation of T cells, NK cells and NKT cells after treatment.
Figure 4 In vivo anti-tumor efficacy of two antibody blockade both CD47 antibody and CD274 antibody in 4T1 tumor cells. (A) Flow cytometry sorting graphs showing how to distinguish unwanted noise from gated. (B) Schema for two antibodies blockade in immunotherapy. (C–E) The percent of T cells, NK cells and NKT cells in leukocyte since the start of the injection (*P < 0.05, **P < 0.01 and ***P < 0.001). (F–H) The percentage activation of T cells, NK cells and NKT cells after treatment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 86

Metadata

Authors
Lian, S., Xie, R., Ye, Y., Lu, Y., Cheng, Y., Xie, X., Li, S., & Jia, L.
Affiliations
  • Fuzhou University (CN)
  • Fujian University of Traditional Chinese Medicine (CN)
  • Minjiang University (CN)
Corresponding author
Jia, Lee
Venue
Scientific Reports
Published
2019-03-14
Volume
9
Issue
1
Pages
4532-4532
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2921760704
Cited by
81
References
29
Citations by year
2026: 8 · 2025: 6 · 2024: 11 · 2023: 14 · 2022: 13 · 2021: 11 · 2020: 14 · 2019: 4
FWCI
4.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (81703555, U1505225, 81773063)
  • China Postdoctoral Science Foundation (2017M620268)
  • Chinese Ministry of Science and Technology | Department of S and T for Social Development (2015CB931804)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
circulating tumor cells, PD-L1, CD47, dual immune checkpoint blockade, cancer immunotherapy, metastasis, 4T1 breast cancer, PD-L1 inhibitors, anti-CD47 antibody, tumor growth inhibition
MeSH terms
Animals, Antibodies, Female, Immunotherapy, Killer Cells, Natural, Mice, Inbred BALB C, Neoplastic Cells, Circulating, Neoplasms, T-Lymphocytes, Transplantation, Homologous, Cell Line, Tumor, Mice, CD47 Antigen, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. https://app.cochat.ai/papers/10.1038/s41598-019-40241-1
The paper
Lian, S., Xie, R., Ye, Y., Lu, Y., Cheng, Y., Xie, X., Li, S., & Jia, L. (2019). Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Scientific Reports. https://doi.org/10.1038/s41598-019-40241-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.